FLT3 and acute myeloid leukemia: A retrospective analysis of AML patients with activating FLT3 mutations presented by Aldoss and co-workers revealed an excellent composite CR (CRc = CR/CRi) rate of 94% for treatment-naïve AML patients undergoing combined treatment with HMA plus venetoclax.